Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
10:56am, Thursday, 19'th Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention
05:38pm, Wednesday, 18'th Jun 2025
LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.
Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead
04:04pm, Wednesday, 18'th Jun 2025
19 Jun
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead
03:41pm, Wednesday, 18'th Jun 2025
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)'s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being officially approved by the US Food and Drug Administrati
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
02:49pm, Wednesday, 18'th Jun 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injecta
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
02:30pm, Wednesday, 18'th Jun 2025
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending t
US FDA approves Gilead's twice-yearly injection for HIV prevention
02:24pm, Wednesday, 18'th Jun 2025
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
11:38am, Wednesday, 18'th Jun 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are
Should You Buy Gilead Stock At $110?
09:15am, Wednesday, 18'th Jun 2025
Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performa
GILD ALERT: Ongoing Investigation Into Gilead Sciences, Inc. - Contact Levi & Korsinsky
10:50am, Tuesday, 17'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Tuesday, 17'th Jun 2025
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company")
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud
01:55pm, Monday, 16'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
01:36pm, Monday, 16'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors ar
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost Money
10:23am, Monday, 16'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning
